<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294396</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-112</org_study_id>
    <nct_id>NCT02294396</nct_id>
  </id_info>
  <brief_title>Post-marketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.</brief_title>
  <official_title>Post-Marketing Study of Mirabegron - Long-term Add-on Therapy With Anticholinergics in Patients With Overactive Bladder Under Treatment With Mirabegron</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and efficacy of add-on therapy with
      anticholinergics in patients with overactive bladder (OAB) on mirabegron.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label study to evaluate the safety and efficacy of add-on therapy
      with anticholinergics in OAB patients on mirabegron.

      The duration of the study period will be 54 weeks in total, comprising a 2-week screening
      period and a 52-week treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2014</start_date>
  <completion_date type="Actual">September 7, 2016</completion_date>
  <primary_completion_date type="Actual">September 7, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by vital signs, adverse events, laboratory values, 12-lead electrocardiogram, QTcF interval, and residual urine volume</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the total OABSS score</measure>
    <time_frame>Week -2, 0, 4, 8, 12, 16, 28, and 52</time_frame>
    <description>OABSS: Overactive bladder symptom score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the OAB-q SF score</measure>
    <time_frame>Week 0, 12, 28, and 52</time_frame>
    <description>OAB-q SF: Overactive bladder questionnaire short form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the mean number of micturition episodes per 24 hours</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 28, 40, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the mean number of urgency episodes per 24 hours</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 28, 40, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the mean number of urinary incontinence episodes per 24 hours</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 28, 40, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the mean number of urgency incontinence episodes per 24 hours</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 28, 40, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the mean volume voided per micturition</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 28, 40, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the mean number of nocturia episodes</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 28, 40, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization rate of OABSS</measure>
    <time_frame>Week -2, 0, 4, 8, 12, 16, 28, and 52</time_frame>
    <description>Definitions of normalization: 1 point or less on Question 3 or the total score of 2 points or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization rate of the number of micturition episodes</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 28, 40, and 52</time_frame>
    <description>Definitions of normalization: The mean number of micturition episodes per 24 hours &lt; 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization rate of the number of urgency episodes</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 28, 40, and 52</time_frame>
    <description>Definitions of normalization: The mean number of urgency episodes per 24 hours = 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization rate of the number of urinary incontinence episodes</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 28, 40, and 52</time_frame>
    <description>Definitions of normalization: The mean number of urinary incontinence episodes per 24 hours = 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization rate of the number of nocturia episodes</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 28, 40, and 52</time_frame>
    <description>Definitions of normalization: The mean number of nocturia episodes per 24 hours = 0</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">649</enrollment>
  <condition>Overactive Bladder (OAB)</condition>
  <arm_group>
    <arm_group_label>Solifenacin add-on group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive orally 1 mirabegron 50 mg tablet once daily after breakfast + 1 solifenacin 5 mg tablet (may be increased to 2 tablets) once daily after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propiverine add-on group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive orally 1 mirabegron 50 mg tablet once daily after breakfast + 1 propiverine 20 mg tablet once daily after breakfast (may be increased to 1 propiverine 20 mg tablet twice daily after breakfast and after dinner).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imidafenacin add-on group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive orally 1 mirabegron 50 mg tablet once daily after breakfast + 1 imidafenacin 0.1 mg tablet (may be increased to 2 tablets) twice daily after breakfast and after dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolterodine add-on group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive orally 1 mirabegron 50 mg tablet once daily after breakfast + 1 tolterodine 4 mg capsule once daily after breakfast (dose increase of tolterodine is not permitted).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron tablet</intervention_name>
    <description>orally administered at a dose of 1 tablet once daily after breakfast</description>
    <arm_group_label>Solifenacin add-on group</arm_group_label>
    <arm_group_label>Propiverine add-on group</arm_group_label>
    <arm_group_label>Imidafenacin add-on group</arm_group_label>
    <arm_group_label>Tolterodine add-on group</arm_group_label>
    <other_name>YM178</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin tablet</intervention_name>
    <description>orally administered at a dose of 1 tablet once daily after breakfast (may be increased to 2 tablets)</description>
    <arm_group_label>Solifenacin add-on group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propiverine tablet</intervention_name>
    <description>orally administered at a dose of 1 tablet once daily after breakfast (may be increased to 1 tablet twice daily after breakfast and after dinner)</description>
    <arm_group_label>Propiverine add-on group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imidafenacin tablet</intervention_name>
    <description>orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (may be increased to 2 tablets twice daily after breakfast and after dinner)</description>
    <arm_group_label>Imidafenacin add-on group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine capsule</intervention_name>
    <description>orally administered at a dose of 1 capsule once daily after breakfast (must not be increased)</description>
    <arm_group_label>Tolterodine add-on group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female: OAB outpatient who has been postmenopausal for at least 1 year

          -  Male: OAB outpatient who has no wish to have children in the future

          -  Patient has been under treatment with mirabegron at a stable dose of 50 mg once daily
             for at least 6 weeks before the start of the screening period

          -  Patient can walk to the bathroom without assistance

          -  Patient has a total Overactive Bladder Symptom Score (OABSS) of ≥3 points and a
             Question 3 score of ≥2 points

        Exclusion Criteria:

          -  Patient has an established diagnosis of stress urinary incontinence (patient has no
             symptom other than stress urinary incontinence)

          -  Patient has urinary tract infection (cystitis, prostatitis, etc.), urinary calculus
             (ureteric calculus, urethral calculus, bladder calculus, etc.), interstitial cystitis,
             or a history of recurrent urinary tract infection (at least 3 episodes within 24 weeks
             before the start of the screening period)

          -  Patient has a residual urine volume of ≥100 mL at week -2 visit or patient with benign
             prostatic hyperplasia or lower urinary tract obstruction

          -  Patient has uncontrolled hypertension (sitting systolic blood pressure ≥180 mmHg or
             diastolic blood pressure ≥110 mmHg at week -2 visit)

          -  Patient has a pulse rate of ≥110 bpm or &lt;50 bpm at week -2 visit

          -  Anticholinergics are contraindicated (urinary retention; obstruction in the pylorus,
             duodenum, or intestine; paralytic ileus; gastric/intestinal atony; myasthenia gravis;
             and decreased gastrointestinal motility/tone, etc.) for the patient.

          -  Patient has glaucoma, ulcerative colitis, hyperthyroidism, dementia, cognitive
             dysfunction, parkinsonism symptoms, or clinically significant cerebrovascular disorder

          -  Patient has serious heart disease (myocardial infarction, cardiac failure,
             uncontrolled angina pectoris, serious arrhythmia, use of pacemaker, etc.), liver
             disease, kidney disease, immunological disease, lung disease, etc. or patient has or
             has a history of malignant tumor (except for malignant tumor that has not been treated
             for at least 5 years before the start of the screening period with no risk of
             recurrence)

          -  Patient has drug hypersensitivity to β-agonists or anticholinergics

          -  Patient is under treatment with flecainide acetate or propafenone hydrochloride

          -  Patient has long QT syndrome, patient is vulnerable to arrhythmia such as bradycardia
             or acute myocardial ischemia, patient has hypokalemia, and patient has ischemic heart
             disease such as angina pectoris

          -  Patient has used any prohibited concomitant medication within 4 weeks before the start
             of the screening period

          -  Patient is under catheterization or intermittent self-catheterization or patient has
             pelvic organ prolapse that affects the urinary tract function

          -  Patient has received radiotherapy that affects the urinary tract function

          -  Patient has received surgical therapy that may affect the urinary tract function
             within 24 weeks before the start of the screening period

          -  Patient has received nonpharmacological therapy for OAB such as electric stimulation
             therapy (interferential low frequency therapy, magnetic stimulation therapy, etc.),
             biofeedback therapy, bladder training, or pelvic floor muscle exercise within 2 weeks
             before the start of the screening period

          -  Patient has or has a history of mood disorder, neurotic disorder, and schizophrenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=224</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <disposition_first_submitted>August 31, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 31, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 6, 2017</disposition_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticholinergic</keyword>
  <keyword>Overactive Bladder (OAB)</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>YM178</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Tolterodine Tartrate</mesh_term>
    <mesh_term>Propiverine</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
    <mesh_term>Cholinergic Antagonists</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 7, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

